应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
AZN 阿斯利康
交易中 07-29 10:00:25 EDT
74.18
+2.35
+3.27%
最高
74.41
最低
72.57
成交量
500.40万
今开
72.94
昨收
71.83
日振幅
2.56%
总市值
2,301亿
流通市值
2,291亿
总股本
31.01亿
成交额
3.67亿
换手率
0.16%
流通股本
30.88亿
市净率
5.61
ROE
19.79%
每股收益
2.48
52周最高
87.68
52周最低
61.24
市盈率
29.85
股息
1.55
股息收益率
0.02
ROA
8.16%
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
阿斯利康上半年中国区收入35.15亿美元 将扩大在华布局
格隆汇 · 10:29
阿斯利康上半年中国区收入35.15亿美元 将扩大在华布局
抗癌“创新药舰队”高歌猛进 助阿斯利康(AZN.US)业绩超预期
智通财经 · 08:02
抗癌“创新药舰队”高歌猛进 助阿斯利康(AZN.US)业绩超预期
阿斯利康2025H1:营收280亿美元!Enhertu大卖22.89亿美元,TSLP单抗增长73%
医药魔方 · 06:48
阿斯利康2025H1:营收280亿美元!Enhertu大卖22.89亿美元,TSLP单抗增长73%
阿斯利康7月28日成交额为5.51亿美元
市场透视 · 01:20
阿斯利康7月28日成交额为5.51亿美元
阿斯利康首席医学官加入BMS
医药魔方Info · 07-26
阿斯利康首席医学官加入BMS
阿斯利康7月25日成交额为4.50亿美元
市场透视 · 07-26
阿斯利康7月25日成交额为4.50亿美元
美股异动 | 百时美施贵宝(BMY.US)跌3% 首席医疗官将于8月1日离职
智通财经 · 07-25
美股异动 | 百时美施贵宝(BMY.US)跌3% 首席医疗官将于8月1日离职
乳腺癌新辅助治疗 阿斯利康(AZN.US)/第一三共HER2 ADC新适应症拟纳入优先审评
智通财经 · 07-25
乳腺癌新辅助治疗 阿斯利康(AZN.US)/第一三共HER2 ADC新适应症拟纳入优先审评
和铂医药午后走强,近期与大冢制药达成BD交易,公司上半年BD总额超66亿美元
智通财经 · 07-25
和铂医药午后走强,近期与大冢制药达成BD交易,公司上半年BD总额超66亿美元
阿斯利康(AZN.US)首创C5补体双抗III期重症肌无力研究成功
智通财经 · 07-24
阿斯利康(AZN.US)首创C5补体双抗III期重症肌无力研究成功
财报前瞻|阿斯利康二季度营收、盈利有望保持增势,重点关注核心药物销售
财报Agent · 07-24
财报前瞻|阿斯利康二季度营收、盈利有望保持增势,重点关注核心药物销售
阿斯利康7月23日成交额为3.65亿美元
市场透视 · 07-24
阿斯利康7月23日成交额为3.65亿美元
呼吸道疫苗市场前景诱人!该头部药企宣布16亿美元收购
制药网 · 07-23
呼吸道疫苗市场前景诱人!该头部药企宣布16亿美元收购
阿斯利康7月22日成交额为2.19亿美元
市场透视 · 07-23
阿斯利康7月22日成交额为2.19亿美元
阿斯利康7月21日成交额为2.21亿美元
市场透视 · 07-22
阿斯利康7月21日成交额为2.21亿美元
阿斯利康投资40亿美元扩建美国医药中心
DoNews · 07-21
阿斯利康投资40亿美元扩建美国医药中心
阿斯利康宣布FLAURA2研究积极结果 奥希替尼联合方案助力肺癌OS改善
智通财经网 · 07-21
阿斯利康宣布FLAURA2研究积极结果 奥希替尼联合方案助力肺癌OS改善
默克对SpringWorks的收购带来了药物批准Merck's SpringWorks takeover delivers a drug approval
动脉网 · 07-21
默克对SpringWorks的收购带来了药物批准Merck's SpringWorks takeover delivers a drug approval
阿斯利康7月17日成交额为2.56亿美元
市场透视 · 07-18
阿斯利康7月17日成交额为2.56亿美元
30起交易近138亿美元!默沙东达成100亿美元大额并购;艾伯维超19亿美元引进三抗管线 | 一周交易
创鉴汇 · 07-17
30起交易近138亿美元!默沙东达成100亿美元大额并购;艾伯维超19亿美元引进三抗管线 | 一周交易
加载更多
公司概况
公司名称:
阿斯利康
所属市场:
NASDAQ
上市日期:
1993-05-12
主营业务:
阿斯利康股份有限公司于1992年6月17日根据1985年《公司法》在英格兰和威尔士注册成立。该公司是在1993年将Imperial化学工业公司的制药、农化和特种化学品业务分拆时成立的。1999年,公司出售了特种化学品业务。同样在1999年,该公司与瑞典Astra公司合并。2000年,该公司将农化业务分拆,并将其与诺华公司的同类业务合并,成立了一家新的公司Syngenta AG。2007年,集团收购了位于美国的生物制剂和疫苗企业MedImmune。2021年,集团收购了位于美国的罕见病企业Alexion。
发行价格:
--
{"stockData":{"symbol":"AZN","market":"US","secType":"STK","nameCN":"阿斯利康","latestPrice":74.18,"timestamp":1753797623687,"preClose":71.83,"halted":0,"volume":5003974,"delay":0,"floatShares":3088278796,"shares":3101341336,"eps":2.484749,"marketStatus":"交易中","change":2.35,"latestTime":"07-29 10:00:25 EDT","open":72.94,"high":74.41,"low":72.57,"amount":367279712.086244,"amplitude":0.025616,"askPrice":74.2,"askSize":1074,"bidPrice":74.16,"bidSize":900,"shortable":3,"etf":0,"ttmEps":2.484749,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1753819200000},"marketStatusCode":2,"adr":1,"adrRate":0.5,"listingDate":737179200000,"exchange":"NASDAQ","adjPreClose":71.83,"dividendRate":0.020895,"preHourTrading":{"tag":"盘前","latestPrice":72.86,"preClose":71.83,"latestTime":"09:29 EDT","volume":1812628,"amount":133070477.49028,"timestamp":1753795799999},"postHourTrading":{"tag":"盘后","latestPrice":71.58,"preClose":71.83,"latestTime":"19:59 EDT","volume":45700,"amount":3283095.5102,"timestamp":1753747167733},"volumeRatio":11.336892,"impliedVol":0.2223,"impliedVolPercentile":0.092},"requestUrl":"/m/hq/s/AZN","defaultTab":"news","newsList":[{"id":"2555657037","title":"阿斯利康上半年中国区收入35.15亿美元 将扩大在华布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2555657037","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555657037?lang=zh_cn&edition=full","pubTime":"2025-07-29 18:29","pubTimestamp":1753784981,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU2236285917.USD","BK4585","LU0109394709.USD","AZN","LU0320765992.SGD","BK4588","BK4568","LU2417539215.USD","LU2462157665.USD","LU1829250122.USD","LU2456880835.USD","LU0889565916.HKD","BK4007"],"gpt_icon":0},{"id":"2555332140","title":"抗癌“创新药舰队”高歌猛进 助阿斯利康(AZN.US)业绩超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2555332140","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555332140?lang=zh_cn&edition=full","pubTime":"2025-07-29 16:02","pubTimestamp":1753776160,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09939","BK1574","LU0109394709.USD","LU2236285917.USD","LU2456880835.USD","159992","LU2462157665.USD","LU1829250122.USD","BK4007","AZN","LU0320765992.SGD","BK1515","LU0889565916.HKD","06978","LU2417539215.USD","159938","BK4568","BK4588","BK1161","BK4585"],"gpt_icon":0},{"id":"2555388080","title":"阿斯利康2025H1:营收280亿美元!Enhertu大卖22.89亿美元,TSLP单抗增长73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2555388080","media":"医药魔方","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555388080?lang=zh_cn&edition=full","pubTime":"2025-07-29 14:48","pubTimestamp":1753771713,"startTime":"0","endTime":"0","summary":"7月29日,阿斯利康公布2025年H1业绩,上半年总营收280.45亿美元,其中产品收入279.63亿美元;研发投入亿美元,同比增长%。若计入第一三共报告的收入,Enhertu上半年销售额为22.89亿美元。其销售额还在起步阶段,在上半年为阿斯利康创收0.14亿美元。Truqap是阿斯利康在肿瘤领域推出的另一支潜力股,上市以来持续发力,上半年畅销3.02亿美元,已接近2024年全年销售额。今年上半年,Beyfortus销售额较同期增长2倍以上,为阿斯利康带来2.38亿美元的收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729145517a6c74492&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729145517a6c74492&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TSLP","AZN"],"gpt_icon":0},{"id":"2555083251","title":"阿斯利康7月28日成交额为5.51亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2555083251","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555083251?lang=zh_cn&edition=full","pubTime":"2025-07-29 09:20","pubTimestamp":1753752036,"startTime":"0","endTime":"0","summary":"美东时间2025年7月28日,阿斯利康成交额为5.51亿美元,成交额较昨日增加22.41%,当日成交量为764.78万股。阿斯利康于2025年7月28日跌1.14%,报71.83美元,该股过去5个交易日涨4.53%,年初至今涨11.42%,过去60日涨0.06%。|近5个交易日成交情况||||#|日期|成交额(美元)|成交额较昨日变化|成交量(股)|#|2025-07-28|5.51亿|22.41%|764.78万|#|2025-07-25|4.50亿|5.61%|620.23万|#|2025-07-24|4.26亿|16.81%|576.71万|#|2025-07-23|3.65亿|66.24%|502.08万|#|2025-07-22|2.19亿|-0.63%|312.67万|1999年,瑞典的Astra和英国的Zeneca集团合并成立了阿斯利康。大部分销售额来自国际市场,其中美国占其销售额的近三分之一。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729092045a6c6c256&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729092045a6c6c256&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2417539215.USD","LU0889565916.HKD","LU2462157665.USD","AZN","LU2236285917.USD","BK4585","LU2456880835.USD","LU0320765992.SGD","LU0109394709.USD","BK4588","LU1829250122.USD","BK4568","BK4007"],"gpt_icon":0},{"id":"2554713979","title":"阿斯利康首席医学官加入BMS","url":"https://stock-news.laohu8.com/highlight/detail?id=2554713979","media":"医药魔方Info","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554713979?lang=zh_cn&edition=full","pubTime":"2025-07-26 11:33","pubTimestamp":1753500813,"startTime":"0","endTime":"0","summary":"7月25日,BMS宣布任命Cristian Massacesi博士为公司的执行副总裁、首席医学官兼全球开发负责人,自2025年8月1日起生效。自2021年起,Massacesi博士担任阿斯利康及其罕见病子公司Alexion的首席医学官,并兼任阿斯利康肿瘤学首席开发官,领导超过3000名员工的全球团队。在他任职期间,阿斯利康推进了150多项临床研究,并获得多项监管批准。Massacesi的加入正值BMS关键节点,该公司正在推进一项总额35亿美元、截至2027年的成本削减计划,其中包括裁员超过2000人。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250726123109a4644796&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250726123109a4644796&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2456880835.USD","LU2236285917.USD","LU2417539215.USD","BK4585","AZN","BK4007","LU0109394709.USD","LU0320765992.SGD","LU0889565916.HKD","BK4588","BK4568","BMS","LU1829250122.USD","LU2462157665.USD"],"gpt_icon":0},{"id":"2554790789","title":"阿斯利康7月25日成交额为4.50亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2554790789","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554790789?lang=zh_cn&edition=full","pubTime":"2025-07-26 09:21","pubTimestamp":1753492883,"startTime":"0","endTime":"0","summary":"美东时间2025年7月25日,阿斯利康成交额为4.50亿美元,成交额较昨日增加5.61%,当日成交量为620.23万股。阿斯利康于2025年7月25日跌1.38%,报72.66美元,该股过去5个交易日涨5.63%,年初至今涨12.7%,过去60日涨1.32%。|近5个交易日成交情况||||#|日期|成交额(美元)|成交额较昨日变化|成交量(股)|#|2025-07-25|4.50亿|5.61%|620.23万|#|2025-07-24|4.26亿|16.81%|576.71万|#|2025-07-23|3.65亿|66.24%|502.08万|#|2025-07-22|2.19亿|-0.63%|312.67万|#|2025-07-21|2.21亿|6.92%|320.55万|1999年,瑞典的Astra和英国的Zeneca集团合并成立了阿斯利康。大部分销售额来自国际市场,其中美国占其销售额的近三分之一。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250726092132a6c26d66&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250726092132a6c26d66&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0109394709.USD","LU2462157665.USD","BK4588","LU2236285917.USD","LU1829250122.USD","BK4568","LU0320765992.SGD","BK4585","AZN","BK4007","LU0889565916.HKD","LU2417539215.USD","LU2456880835.USD"],"gpt_icon":0},{"id":"2554952227","title":"美股异动 | 百时美施贵宝(BMY.US)跌3% 首席医疗官将于8月1日离职","url":"https://stock-news.laohu8.com/highlight/detail?id=2554952227","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554952227?lang=zh_cn&edition=full","pubTime":"2025-07-25 23:25","pubTimestamp":1753457139,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0109394709.USD","LU1093756168.USD","LU0267386448.USD","LU2417539215.USD","LU0306806265.USD","LU0114720955.EUR","LU0868494617.USD","LU2456880835.USD","BK4534","LU0882574055.USD","LU0237698245.USD","LU2242652126.USD","BK4559","BMY","IE0002141913.USD","LU0061475181.USD","IE0009355771.USD","LU0889565916.HKD","LU1074936037.SGD","LU0306807586.USD","LU0321505868.SGD","LU2125154778.USD","LU0096364046.USD","LU1670710661.SGD","AZN","LU0321505439.SGD","LU1829250122.USD","159891","IE00BFXG1179.USD","LU1868836591.USD","BK4532","LU1093756325.SGD","LU0320765992.SGD","LU2360032135.SGD","LU1585245621.USD","LU1323610961.USD","BK4588","BK4007","BK4568","IE00BJT1NW94.SGD","LU0225284248.USD","LU1261432733.SGD","LU1868837136.USD","LU2125154935.USD","LU2236285917.USD","LU2133065610.SGD","LU1032466523.USD","BK4585","LU0225771236.USD","IE00BSNM7G36.USD"],"gpt_icon":0},{"id":"2554760238","title":"乳腺癌新辅助治疗 阿斯利康(AZN.US)/第一三共HER2 ADC新适应症拟纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2554760238","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554760238?lang=zh_cn&edition=full","pubTime":"2025-07-25 21:13","pubTimestamp":1753449186,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,7月25日,国家药品监督管理局(NMPA)药品审评中心(CDE)官网显示,第一三共与阿斯利康(AZN.US)共同开发的德曲妥珠单抗被纳入拟优先审评行列,用于HER2阳性乳腺癌患者新辅助治疗。医药魔方数据库显示,德曲妥珠单抗已在我国获批了4项适应症,其中两项是乳腺癌相关适应症,分别为:适用于治疗既往接受过一种或多种抗HER2治疗方案的不可切除或转移性HER2阳性乳腺癌成年患者、用于治疗既往在转移性疾病阶段接受过至少一种系统治疗的,或在辅助化疗期间或完成辅助化疗之后6个月内复发的,不可切除或转移性HER2低表达(IHC 1+或IHC 2+/ISH-)成人乳腺癌患者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1322193.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4080","LU2456880835.USD","LU0109394709.USD","LU2236285917.USD","BK4568","LU0320765992.SGD","LU2462157665.USD","LU1829250122.USD","BK4231","BK4588","ADC","BK4585","LU2417539215.USD","AZN","LU0889565916.HKD","BK4007"],"gpt_icon":0},{"id":"2554768187","title":"和铂医药午后走强,近期与大冢制药达成BD交易,公司上半年BD总额超66亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2554768187","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554768187?lang=zh_cn&edition=full","pubTime":"2025-07-25 14:17","pubTimestamp":1753424220,"startTime":"0","endTime":"0","summary":"$和铂医药-B $ 午后一度涨超8%,成交额1.82亿港元消息面上,今年6月,和铂医药宣布,公司与大冢制药达成全球战略合作。大冢制药将以4700万美元的首付款和里程碑付款获得在全球范围内开发、生产和商业化HBM7020的独家许可,其他额外付款高达6.23亿美元。2025年上半年,和铂达成多笔BD交易,包括TSLP单抗9.7亿美元、阿斯利康45.75亿美元、CRH疗法3.95亿美元及TCE双抗6.7亿美元,BD总金额超过66亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725170423a4630187&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725170423a4630187&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0889565916.HKD","BK4568","BK4585","AZN","LU2462157665.USD","BK4007","BK4588","LU0320765992.SGD","LU2417539215.USD","LU2456880835.USD","LU2236285917.USD","LU1829250122.USD","LU0109394709.USD"],"gpt_icon":0},{"id":"2553225783","title":"阿斯利康(AZN.US)首创C5补体双抗III期重症肌无力研究成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2553225783","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553225783?lang=zh_cn&edition=full","pubTime":"2025-07-24 21:15","pubTimestamp":1753362942,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,7月24日,阿斯利康宣布gefurulimab的III期临床试验在抗乙酰胆碱受体抗体阳性(Ab+)的全身型重症肌无力成人患者中取得积极结果。全身型重症肌无力是一种罕见、使人衰弱、慢性的自身免疫性神经肌肉疾病,会导致肌肉功能丧失和严重无力。gMG患者最初可能出现言语不清、复视、眼睑下垂和无力等症状,随着疾病进展,症状会变得更加严重,包括极度疲劳、吞咽困难、窒息和呼吸衰竭。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1321701.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2236285917.USD","BK4585","LU0109394709.USD","AZN","LU0320765992.SGD","BK4134","BK4588","BK4568","LU2417539215.USD","LU2462157665.USD","LU1829250122.USD","LU2456880835.USD","III","LU0889565916.HKD","BK4007"],"gpt_icon":0},{"id":"1143511393","title":"财报前瞻|阿斯利康二季度营收、盈利有望保持增势,重点关注核心药物销售","url":"https://stock-news.laohu8.com/highlight/detail?id=1143511393","media":"财报Agent","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143511393?lang=zh_cn&edition=full","pubTime":"2025-07-24 13:21","pubTimestamp":1753334514,"startTime":"0","endTime":"0","summary":"阿斯利康将于7月29日盘前发布二季度财报。","market":"us","thumbnail":"https://static.tigerbbs.com/eba364c775e7abae5c1bc88bce8273f4","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/eba364c775e7abae5c1bc88bce8273f4"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN"],"gpt_icon":0},{"id":"2553221223","title":"阿斯利康7月23日成交额为3.65亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2553221223","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553221223?lang=zh_cn&edition=full","pubTime":"2025-07-24 09:20","pubTimestamp":1753320009,"startTime":"0","endTime":"0","summary":"美东时间2025年7月23日,阿斯利康成交额为3.65亿美元,成交额较昨日增加66.24%,当日成交量为502.08万股。阿斯利康于2025年7月23日涨3.58%,报73.0美元,该股过去5个交易日涨4.17%,年初至今涨13.23%,过去60日涨4.93%。|近5个交易日成交情况||||#|日期|成交额(美元)|成交额较昨日变化|成交量(股)|#|2025-07-23|3.65亿|66.24%|502.08万|#|2025-07-22|2.19亿|-0.63%|312.67万|#|2025-07-21|2.21亿|6.92%|320.55万|#|2025-07-18|2.07亿|-19.30%|299.22万|#|2025-07-17|2.56亿|2.81%|369.87万|1999年,瑞典的Astra和英国的Zeneca集团合并成立了阿斯利康。大部分销售额来自国际市场,其中美国占其销售额的近三分之一。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724092011a6be7de6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724092011a6be7de6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LU0320765992.SGD","LU1829250122.USD","LU2417539215.USD","LU2236285917.USD","BK4585","LU0889565916.HKD","BK4568","LU2462157665.USD","LU2456880835.USD","BK4588","LU0109394709.USD","AZN"],"gpt_icon":0},{"id":"2553291218","title":"呼吸道疫苗市场前景诱人!该头部药企宣布16亿美元收购","url":"https://stock-news.laohu8.com/highlight/detail?id=2553291218","media":"制药网","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553291218?lang=zh_cn&edition=full","pubTime":"2025-07-23 14:35","pubTimestamp":1753252549,"startTime":"0","endTime":"0","summary":"近期,制药企业在呼吸道疫苗市场动作频频,展现出对该领域的高度重视与大力投入。如2025 年 7 月 22 日,赛诺菲公司宣布,将以高达 16 亿美元的价格收购英国生物技术公司 Vicebio Ltd. 。此次收购进一步巩固了赛诺菲在呼吸道病毒疫苗市场的布局,推动其更接近研发出新一代能在一次注射中为人体提供对多种呼吸道病毒防护的疫苗。分析指出,呼吸道疾病的高发性和严重性是制药企业加大投入的重要原因。从市场前景来看,呼吸道疫苗市场潜力巨大。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072314383697b1eb62&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072314383697b1eb62&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MRK","ICVX","JNJ","GSK.UK","BK4539","LU1829250122.USD","BK4139","BK4532","BK4588","BK4585","GSK","AZN","VLP","BK4007"],"gpt_icon":0},{"id":"2553262450","title":"阿斯利康7月22日成交额为2.19亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2553262450","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553262450?lang=zh_cn&edition=full","pubTime":"2025-07-23 09:19","pubTimestamp":1753233591,"startTime":"0","endTime":"0","summary":"美东时间2025年7月22日,阿斯利康成交额为2.19亿美元,成交额较昨日减少0.63%,当日成交量为312.67万股。阿斯利康于2025年7月22日涨2.56%,报70.48美元,该股过去5个交易日涨0.23%,年初至今涨9.32%,过去60日涨1.34%。|近5个交易日成交情况||||#|日期|成交额(美元)|成交额较昨日变化|成交量(股)|#|2025-07-22|2.19亿|-0.63%|312.67万|#|2025-07-21|2.21亿|6.92%|320.55万|#|2025-07-18|2.07亿|-19.30%|299.22万|#|2025-07-17|2.56亿|2.81%|369.87万|#|2025-07-16|2.49亿|10.48%|354.30万|1999年,瑞典的Astra和英国的Zeneca集团合并成立了阿斯利康。大部分销售额来自国际市场,其中美国占其销售额的近三分之一。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723091953a6bc0214&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723091953a6bc0214&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2462157665.USD","LU0889565916.HKD","LU1829250122.USD","BK4585","BK4568","LU2456880835.USD","LU0320765992.SGD","LU2236285917.USD","LU0109394709.USD","BK4588","BK4007","LU2417539215.USD","AZN"],"gpt_icon":0},{"id":"2553885232","title":"阿斯利康7月21日成交额为2.21亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2553885232","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553885232?lang=zh_cn&edition=full","pubTime":"2025-07-22 09:19","pubTimestamp":1753147169,"startTime":"0","endTime":"0","summary":"美东时间2025年7月21日,阿斯利康成交额为2.21亿美元,成交额较昨日增加6.92%,当日成交量为320.55万股。阿斯利康于2025年7月21日跌0.1%,报68.72美元,该股过去5个交易日跌4.21%,年初至今涨6.59%,过去60日涨0.31%。|近5个交易日成交情况||||#|日期|成交额(美元)|成交额较昨日变化|成交量(股)|#|2025-07-21|2.21亿|6.92%|320.55万|#|2025-07-18|2.07亿|-19.30%|299.22万|#|2025-07-17|2.56亿|2.81%|369.87万|#|2025-07-16|2.49亿|10.48%|354.30万|#|2025-07-15|2.25亿|-7.72%|319.20万|1999年,瑞典的Astra和英国的Zeneca集团合并成立了阿斯利康。大部分销售额来自国际市场,其中美国占其销售额的近三分之一。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722091937a45adc79&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722091937a45adc79&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1829250122.USD","LU2236285917.USD","BK4007","LU0320765992.SGD","BK4585","LU2417539215.USD","BK4588","LU0109394709.USD","LU0889565916.HKD","LU2462157665.USD","BK4568","LU2456880835.USD","AZN"],"gpt_icon":0},{"id":"2553041524","title":"阿斯利康投资40亿美元扩建美国医药中心","url":"https://stock-news.laohu8.com/highlight/detail?id=2553041524","media":"DoNews","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553041524?lang=zh_cn&edition=full","pubTime":"2025-07-22 05:54","pubTimestamp":1753134842,"startTime":"0","endTime":"0","summary":"2025年7月22日,阿斯利康(AZN.LN)宣布将投资40亿美元用于扩建位于美国弗吉尼亚州的医药生产中心。此次投资旨在提升公司在北美市场的药品生产能力,并加速创新药物的全球供应。尽管消息公布后市场反应平稳,阿斯利康ADR美股盘后微跌0.03%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722055727954bb75d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722055727954bb75d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","LU0109394709.USD","LU1829250122.USD","BK4568","LU2456880835.USD","AZN","LU2417539215.USD","BK4588","BK4007","LU2236285917.USD","LU0320765992.SGD","LU2462157665.USD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2553472400","title":"阿斯利康宣布FLAURA2研究积极结果 奥希替尼联合方案助力肺癌OS改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2553472400","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553472400?lang=zh_cn&edition=full","pubTime":"2025-07-21 21:12","pubTimestamp":1753103570,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,7月21日,阿斯利康宣布III期FLAURA2研究最终总生存期分析取得积极结果:在一线治疗局部晚期或转移性表皮生长因子受体突变非小细胞肺癌患者中,奥希替尼联合培美曲塞和铂类化疗相较于奥希替尼单药治疗在关键次要终点OS方面显示出统计学显著和临床意义的改善。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721212108954b2294&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721212108954b2294&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2456880835.USD","AZN","LU2462157665.USD","BK4588","LU0320765992.SGD","LU2417539215.USD","BK4568","BK4007","LU0889565916.HKD","LU1829250122.USD","BK4585","LU0109394709.USD","LU2236285917.USD"],"gpt_icon":0},{"id":"2553647102","title":"默克对SpringWorks的收购带来了药物批准Merck's SpringWorks takeover delivers a drug approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2553647102","media":"动脉网","labels":["corporation","productRelease","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553647102?lang=zh_cn&edition=full","pubTime":"2025-07-21 19:08","pubTimestamp":1753096080,"startTime":"0","endTime":"0","summary":"Merck KGaA's acquisition of SpringWorks has only just closed, but has already added a new medicine to its portfolio as it gets an EU approval for rare disease therapy Ezmekly.默克公司收购SpringWorks刚刚完成,但其罕见病疗法Ezmekly已获得欧盟批准,为公司的产品组合新增了一种药物。NF1 causes tumours to develop on the covering of nerve cells, leading to disfigurement and other debilitating complications like pain, motor dysfunction, and malignant peripheral nerve sheath cancers. There are approximately 135,000 people in the EU living with the condition, according to Merck, and their lifetime risk of developing PN is approximately 30% to 50%.NF1导致神经细胞覆盖层上出现肿瘤,造成毁容和其他衰弱并发症,如疼痛、运动功能障碍和恶性外周神经鞘癌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072119092297ae9d88&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072119092297ae9d88&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BLSP4239.USD","LU1066051498.USD","LU1934455863.HKD","LU0320765489.SGD","LU1035773651.USD","SG9999001176.SGD","IE00B1BXHZ80.USD","LU2461242641.AUD","IE0002141913.USD","LU1037948541.HKD","BK4534","SG9999002224.SGD","BK4568","SG9999013999.USD","LU1941712348.USD","IE00BBT3K403.USD","LU0106261372.USD","LU0965509010.AUD","LU1934455194.USD","LU0122379950.USD","LU1983299246.USD","LU2456880835.USD","BK4585","IE00BJT1NW94.SGD","LU1989772840.SGD","AZN","LU0208291251.USD","LU0109394709.USD","LU1061106388.HKD","LU0266013472.USD","LU1069347547.HKD","LU0098860793.USD","IE00BFTCPJ56.SGD","SG9999014575.USD","LU1116320901.HKD","LU0070302665.USD","MRK","LU1093756168.USD","IE00BSNM7G36.USD","LU1699723380.USD","LU0320765646.SGD","SG9999001176.USD","LU1116320737.USD","LU1929549753.HKD","LU0006306889.USD","BK4550","IE000M9KFDE8.USD","IE0009355771.USD","LU1989772923.USD","LU0985320562.USD"],"gpt_icon":0},{"id":"2552583014","title":"阿斯利康7月17日成交额为2.56亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2552583014","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552583014?lang=zh_cn&edition=full","pubTime":"2025-07-18 09:19","pubTimestamp":1752801552,"startTime":"0","endTime":"0","summary":"美东时间2025年7月17日,阿斯利康成交额为2.56亿美元,成交额较昨日增加2.81%,当日成交量为369.87万股。阿斯利康于2025年7月17日跌1.17%,报69.26美元,该股过去5个交易日跌3.55%,年初至今涨7.43%,过去60日涨3.53%。|近5个交易日成交情况||||#|日期|成交额(美元)|成交额较昨日变化|成交量(股)|#|2025-07-17|2.56亿|2.81%|369.87万|#|2025-07-16|2.49亿|10.48%|354.30万|#|2025-07-15|2.25亿|-7.72%|319.20万|#|2025-07-14|2.44亿|26.16%|340.19万|#|2025-07-11|1.94亿|-33.45%|272.99万|1999年,瑞典的Astra和英国的Zeneca集团合并成立了阿斯利康。大部分销售额来自国际市场,其中美国占其销售额的近三分之一。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718091922a6b0d50c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718091922a6b0d50c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","BK4007","LU2417539215.USD","BK4585","LU2462157665.USD","LU1829250122.USD","BK4588","LU0109394709.USD","AZN","LU2236285917.USD","LU0320765992.SGD","LU0889565916.HKD","LU2456880835.USD"],"gpt_icon":0},{"id":"2552488142","title":"30起交易近138亿美元!默沙东达成100亿美元大额并购;艾伯维超19亿美元引进三抗管线 | 一周交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2552488142","media":"创鉴汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552488142?lang=zh_cn&edition=full","pubTime":"2025-07-17 17:23","pubTimestamp":1752744181,"startTime":"0","endTime":"0","summary":"据创鉴汇不完全统计,7月7日至7月13日全球生物制药领域共披露30起交易事件,潜在交易总额近138亿美元。上周最重磅的交易当属默沙东以100亿美元收购Verona Pharma,这也是2025年迄今创新药领域第二大并购。本次交易不仅巩固了默沙东在心肺疾病领域的产品管线,还进一步强化了其在慢性疾病治疗市场的竞争优势。上周CGT领域交易增多,涉及4起基因疗法技术合作,1起CAR-T领域并购及1起干细胞移植治疗的合作研发。上周中国公司达成多起跨国交易。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717173302a6af7815&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717173302a6af7815&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0965508806.USD","LU1162221912.USD","LU1066051811.HKD","LU2023250504.SGD","LU2417539215.USD","LU1057294990.SGD","SG9999001440.SGD","LU0965509283.SGD","LU2324357040.USD","SG9999015341.SGD","AZN","BK4585","LU1699723380.USD","IE00BJJMRZ35.SGD","LU2023250843.SGD","SG9999015358.SGD","MRK","LU0265550946.USD","LU1066051225.USD","SG9999013999.USD","LU0234572021.USD","LU0266013472.USD","IE00BLSP4452.SGD","IE00BN8TJ469.HKD","LU0238689110.USD","LU1023059063.AUD","LU0058720904.USD","LU0203345920.USD","SG9999014567.USD","LU1989771016.USD","LU2361044865.SGD","LU2461242641.AUD","LU1829250122.USD","LU0320765489.SGD","LU2112291526.USD","LU2361045086.USD","LU1291159041.SGD","SG9999002224.SGD","IE0009355771.USD","LU1941712264.USD","LU2106854487.HKD","LU2236285917.USD","BK4007","02616","LU0208291251.USD","LU2468319806.SGD","LU0889565916.HKD","LU0265550359.USD","LU1934455277.USD","LU1974910355.USD","IE00BFTCPJ56.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.astrazeneca.com","stockEarnings":[{"period":"1week","weight":0.0453},{"period":"1month","weight":0.0283},{"period":"3month","weight":0.0017},{"period":"6month","weight":0.0225},{"period":"1year","weight":-0.0806},{"period":"ytd","weight":0.0963}],"compareEarnings":[{"period":"1week","weight":0.013},{"period":"1month","weight":0.0358},{"period":"3month","weight":0.149},{"period":"6month","weight":0.0584},{"period":"1year","weight":0.1699},{"period":"ytd","weight":0.0868}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"阿斯利康股份有限公司于1992年6月17日根据1985年《公司法》在英格兰和威尔士注册成立。该公司是在1993年将Imperial化学工业公司的制药、农化和特种化学品业务分拆时成立的。1999年,公司出售了特种化学品业务。同样在1999年,该公司与瑞典Astra公司合并。2000年,该公司将农化业务分拆,并将其与诺华公司的同类业务合并,成立了一家新的公司Syngenta AG。2007年,集团收购了位于美国的生物制剂和疫苗企业MedImmune。2021年,集团收购了位于美国的罕见病企业Alexion。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.001428},{"month":2,"riseRate":0.40625,"avgChangeRate":-0.017129},{"month":3,"riseRate":0.5625,"avgChangeRate":0.027992},{"month":4,"riseRate":0.65625,"avgChangeRate":0.031251},{"month":5,"riseRate":0.53125,"avgChangeRate":0.008752},{"month":6,"riseRate":0.454545,"avgChangeRate":0.018335},{"month":7,"riseRate":0.606061,"avgChangeRate":-0.00306},{"month":8,"riseRate":0.46875,"avgChangeRate":0.002026},{"month":9,"riseRate":0.5625,"avgChangeRate":0.002514},{"month":10,"riseRate":0.53125,"avgChangeRate":0.013465},{"month":11,"riseRate":0.5,"avgChangeRate":-0.000033},{"month":12,"riseRate":0.5625,"avgChangeRate":0.007964}],"exchange":"NASDAQ","name":"阿斯利康","nameEN":"AstraZeneca PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.4","shortVersion":"4.34.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"阿斯利康,AZN,阿斯利康股票,阿斯利康股票老虎,阿斯利康股票老虎国际,阿斯利康行情,阿斯利康股票行情,阿斯利康股价,阿斯利康股市,阿斯利康股票价格,阿斯利康股票交易,阿斯利康股票购买,阿斯利康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}